I don’t disagree with your theme but in context if that quote it’s worth remembering that Pharma usually outputs antibodies to drug targets

It could still be 500 slides. But presented at the speed of his brain!

What took Xenium so long to get protein panels out? These were touted several years ago

- Resources taken from Xenium?
- Resources in Xenium but needed for other features or bugs to fix?
- Chemistry was poorly optimized for dev teams to finalized?

But one answer can’t be true: lack of demand.

“Cry, the beloved country, these things are not yet at an end”

Alan Paton

Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study | Standard BioTools Inc. The Investor Relations website contains information about Standard BioTools Inc.'s business for stockholders, potential investors, and financial analysts.

Just saw that Somalogic nabbed a big win 👏

1. Big non European cohort doing proteomics 👍
2. Competition where SomaScan won 🥇
3. But now Illumina buying Somalogic to run on NGS🦈
4. But why generate this data on a microarray platform w limited future? 🤷‍♀️

investors.standardbio.com/news-release...

Your users can simply choose on price/performance

Regardless of the results, why would you NOT offer PIPseq as a service given not barriers to start this protocol?

Company posting message about how important their products are

…and backing this up with a picture of their Chief-anything-Officer with a quote about how much we should believe this

#imsold!

🐮

What Makes Someone Cool? A New Study Offers Clues.

Now waiting for some GWAS studies followed to find cool genes, followed by analyses on how coolness is confounded by mating behavior 😎

www.nytimes.com/2025/06/30/w...

Where illumina could struggle culturally is to do product development beyond the current somalogic kit going around. They indicate this so let’s see

I think it’s an old perception that illumina reps can only sell boxes. Illumina run rate is pretty high per instruments and they are less focused on new sites but upgrading and developing business around each sequencer

So we will see illumina at HUPO this year?

In all cases you already know that library prep balloons well above sequencing costs compared to classic methods illumina is already doing prep kits for

Like with spatial and single cell, they don’t need to, do they? They just need a bigger slice of the library prep pie

You’re a bright star in this sky. Keep posting!!

Such timing.

Not the LinkedIn part though, that’s still boring

Call me heartless if you want, but I’m a bit jaded with this pitch:

“Someone I knew had a disease, so I started a company…”

Imagine if people were honest on LinkedIn:

Instead of congratulating someone on their new role,
“This person burned their bridges”

Till then, LinkedIn is just one big self-advertising platform

🐮

So you can hide a wedding ring in there and…

Were you not allowed to enter the mass spec conference? 🤣

In the future (next year) we have live captioning

#eshg2025

Milan in May ☀️ or Boston in October? #eshg25

(Actually Boston is simply beautiful in October) 🍁

You can’t eat microchips. Social media can’t heal the sick. B2B SaaS will never love you

The final measure of any technology is the value it creates, directly or indirectly, for living things. In this sense, biology is everyone’s mission

- Don’t screen for a collection of unrelated diseases
- Target an area that has clinical pathway already and accompanies existing test
- Focus on identifying patients for more attention not less
- Don’t target PCPs
- Utility cannot be “live healthier”

So if we naively think we can develop these with a myriad of techniques available now and demonstrate POC vs genomics, we will get impatient again about the sluggish uptake

Excited and bearish on proteomics risk scores. I hear how they compare favorably to polygenic risk scores

But, polygenic risk scores already perform far better than incumbents

Performance isn’t the issue
To be clear, proteins have many advantages (dynamic, possible with existing dx infrastructure

Possibly the consultants did well ,though

A relief, followed with regret on wasting energy on emergency meetings for many, I’ll bet

Meanwhile illumina isn’t likely to do well in China for a while yet, not just for instruments but probably also consumables

Last I read of Vinay Prasad he was generally against large genomics panels for cancer testing - though with reasonable rebuttals

Wow his career really took a turn (and off!) from those days!

So if there measures of this paper don’t matter with unknown specificity, what should my take on it be?

CVs would suggest false sense of security.